VYT — Vytrus Biotech SA Income Statement
0.000.00%
- €24.17m
- €23.42m
- €5.04m
- 87
- 17
- 91
- 76
Annual income statement for Vytrus Biotech SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.7 | 2.8 | 3.68 | 3.74 | 5.04 |
Cost of Revenue | |||||
Gross Profit | 1.5 | 2.38 | 3.03 | 3.12 | 4.14 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.5 | 2.37 | 3.04 | 3.28 | 4.04 |
Operating Profit | 0.208 | 0.43 | 0.645 | 0.454 | 1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 0.092 | 0.309 | 0.453 | 0.308 | 0.902 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.217 | 0.45 | 0.605 | 0.545 | 1.02 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.217 | 0.45 | 0.605 | 0.545 | 1.02 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.217 | 0.45 | 0.605 | 0.545 | 1.02 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.027 | 0.065 | 0.088 | 0.079 | 0.136 |